Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Xilio Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 41
- −1 vs. Q4 2021
- Shares held
- 18.8M
- −216.4K (−1.1%) vs. Q4 2021
- Total value
- $132.7M
- −$170.4M (−56.2%) vs. Q4 2021
- New holders
- 3
- 8 more added
- Sold out
- 4
- 13 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citigroup Inc | 323 | $2.00K | 0.00% | −1,871−85.3% | Reduced |
| Royal Bank of Canada | 470 | $3.00K | 0.00% | −1,115−70.3% | Reduced |
| Ameritas Investment Partners, Inc. | 573 | $4.00K | 0.00% | 00.0% | Unchanged |
| Legal & General Group Plc | 698 | $5.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 964 | $7.00K | 0.00% | −3,013−75.8% | Reduced |
| Barclays PLC | 1,243 | $8.00K | 0.00% | +1,243 | New |
| Amalgamated Bank | 1,078 | $8.00K | 0.00% | +1,078 | New |
| Amalgamated Financial Corp. | 1,078 | $8.00K | 0.00% | +1,078 | New |
| Wells Fargo & Company | 1,663 | $12.0K | 0.00% | −2,799−62.7% | Reduced |
| STRS Ohio | 1,700 | $12.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 2,104 | $14.0K | 0.00% | +1,066+102.7% | Added |
| Bank of America Corp | 2,611 | $19.0K | 0.00% | −2,163−45.3% | Reduced |
| California State Teachers Retirement System | 3,208 | $23.0K | 0.00% | −870−21.3% | Reduced |
| American International Group, Inc. | 3,795 | $27.0K | 0.00% | −149−3.8% | Reduced |
| Deutsche Bank AG | 4,026 | $28.0K | 0.00% | −482−10.7% | Reduced |
| Tower Research Capital LLC (TRC) | 4,294 | $30.0K | 0.00% | +3,333+346.8% | Added |
| JPMorgan Chase & Co | 4,844 | $34.0K | 0.00% | −6,842−58.5% | Reduced |
| New York State Common Retirement Fund | 5,632 | $40.0K | 0.00% | +64+1.1% | Added |
| Granite Point Capital Management, L.P. | 10,000 | $71.0K | 0.04% | 00.0% | Unchanged |
| Nuveen Asset Management, LLC | 11,284 | $80.0K | 0.00% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 16,100 | $114.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 21,029 | $149.0K | 0.00% | +6,791+47.7% | Added |
| Northern Trust Corp | 63,573 | $449.0K | 0.00% | +539+0.9% | Added |
| State Street Corp | 93,861 | $664.0K | 0.00% | +34,651+58.5% | Added |
| Geode Capital Management, LLC | 141,710 | $1.00M | 0.00% | +7,525+5.6% | Added |
| Monashee Investment Management LLC | 163,066 | $1.15M | 0.33% | −51,187−23.9% | Reduced |
| FIL Ltd | 218,705 | $1.55M | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 299,756 | $2.12M | 0.00% | −24,338−7.5% | Reduced |
| Norges Bank | 400,000 | $2.83M | 0.00% | 00.0% | Unchanged |
| Harvard Management Co Inc | 416,059 | $2.94M | 0.30% | 00.0% | Unchanged |
| Vanguard Group Inc | 416,393 | $2.94M | 0.00% | −7,831−1.8% | Reduced |
| Artal Group S.A. | 450,000 | $3.18M | 0.13% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 477,495 | $3.38M | 0.52% | 00.0% | Unchanged |
| AJU IB Investment Co., Ltd. | 667,742 | $4.72M | 7.29% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 1,191,094 | $8.42M | 0.21% | 00.0% | Unchanged |
| RiverVest Venture Management LLC | 1,441,444 | $10.2M | 10.46% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 2,002,217 | $14.2M | 0.31% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 2,078,692 | $14.7M | 0.33% | −75,369−3.5% | Reduced |
| FMR LLC | 2,590,722 | $18.3M | 0.00% | +20,452+0.8% | Added |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $19.5M | 2.47% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $19.8M | 1.93% | 00.0% | Unchanged |
| Caas Capital Management LP | 0 | $0 | 0.00% | −37,019−100.0% | Sold out |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Davidson Kempner Capital Management LP | 0 | $0 | 0.00% | −29,000−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −20,189−100.0% | Sold out |